IFITM3 and prostate carcinoma: IFITM3 is thus a regulator of the TGFβ/Smad/MAPK signaling pathway through the direct interaction between IFITM3 and Smad4, promoting the EMT, cell proliferation, migration and bone metastasis in prostate cancer (63).